-
Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025
11 Dec 2025 12:00 GMT
… as a key post-treatment resistance mechanism, as … 47;#1Publications About Purple Biotech Purple Biotech Ltd. (NASDAQ… and in combination with cetuximab, in which NT219 … Drug Administration or any other applicable regulator of pharmaceutical products …
-
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
04 Dec 2025 12:00 GMT
… unique multi-arm design in treatment-resistant cancers
REHOVOT, … GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) … upcoming European Society of Medical Oncology Immuno-Oncology ( … and in combination with cetuximab, in which NT219 …
-
<![CDATA[Rx Road Map: Adagrasib With Cetuximab for KRAS G12C-Mutated mCRC]]>
03 Dec 2025 19:41 GMT
… /2 KRYSTAL-1 trial (NCT03785249), upon which the … equipment and medications are readily available before initiating treatment. Premedicate … fda.gov/drugs/;resources-information-approved-drugs/fda-grants-accelerated-approval-adagrasib-cetuximab …
-
Colorectal Cancer Drugs Market to hit US$ 19.96 billion by 2033, (CAGR of 5.2%)
02 Dec 2025 07:21 GMT
… pipeline of novel drugs under clinical trials focusing on better … market.Strong presence of pharmaceutical companies and advanced … combination with cetuximab and mFOLFOX6, for the treatment of … between pharma and biotech companies to develop combination …
-
SanegeneBio raises $110m for RNAi, plus other financings
12 Dec 2025 14:36 GMT
… Eli Lilly.
SanegeneBio, a biotech company with operations in … drug for high blood pressure called SGB-3908, which started human trials … Temasek, HSG, MPCi, Medicxi, and the venture capital … anti-EGFR antibody Erbitux (cetuximab).
San Diego-based BlossomHill …
-
Anticancer Drugs Market Set to Expand at 9.14% CAGR, Reaching USD 401.32 Billion by 2034
21 Nov 2025 13:00 GMT
… drugs, making treatment more accessible. Focus on personalised medicine: … and emerging economies. Pharmaceutical companies are also … therapy
FDA approved
NCT05257408
Encora + Cetuximab
Colorectal … . Clinical Trials & Approval Clinical trials start with …
-
Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update
14 Nov 2025 13:00 GMT
… in patient-derived, treatment-resistant head and neck … with pembrolizumab (Keytruda) or cetuximab (Erbitux)
The Phase … Drug Administration or any other applicable regulator of pharmaceutical … Contact:
IR@purple-biotech.com
Purple Biotech Ltd.
Condensed …
-
Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
12 Nov 2025 13:00 GMT
… , including petosemtamab and cetuximab.
Clinical responses were … agonist drug candidate designed for the treatment of obesity … timing for completion of trials and presentation of data … daniel@lifesciadvisors.com
Corbus Pharmaceuticals Holdings, Inc.
Condensed …
-
Cancer Gene Therapy Market Size to hit $19.97 Billion by 2033 | Key Drivers, Trends, Precision Oncology & FDA
30 Oct 2025 07:32 GMT
… FDA approved a combination therapy of adagrasib and cetuximab … maturing regulatory landscape. Pharmaceutical giants such as Novartis … , and active clinical trials.
Europe (34.5% … science, and biotechnology to redefine oncology treatment. While challenges …
-
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
29 Oct 2025 11:33 GMT
… immune response. About Purple Biotech Purple Biotech Ltd. (NASDAQ… 2 study for the treatment of pancreatic ductal adenocarcinoma … and in combination with cetuximab, in which NT219 … Drug Administration or any other applicable regulator of pharmaceutical …
About
© 1995-2025